title: NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94).
abstract: OBJECTIVE
  We conducted a phase II multicentre study of gemcitabine in patients with anaplastic astrocytoma and glioblastoma multiforme at first relapse.
  
  
  METHODS
  Patients with anaplastic astrocytoma or glioblastoma multiforme receiving a stable dose of steroids and ECOG performance status < or = 3 were eligible for this study at the time of first relapse. One adjuvant chemotherapy regimen was permissible. Patients received gemcitabine 1000 mg/m2 i.v. weekly x 3, repeated on a four-weekly cycle.
  
  
  RESULTS
  Of 20 patients enrolled, 15 were evaluable for response, 19 for non-hematological toxicity and 18 for hematological toxicity. Seven patients had anaplastic astrocytoma (AA) and twelve glioblastoma multiforme (GBM). Age ranged from 28-71 years (median 50). Fifteen patients discontinued therapy due to disease progression. The median number of cycles administered was 1 (range 1-11); only two patients received more than three cycles. Hematologic toxicity was acceptable and no grade 4 toxicity was seen. One patient developed Pneumocystis pneumonia and eventual pulmonary embolism; one died of gastric hemorrhage related to steroid therapy. No objective responses were seen. Nine patients had stable disease (median duration 2.7 months, range 0.9-11.2).
  
  
  CONCLUSIONS
  Gemcitabine given in this dose and schedule seems well tolerated but is not active in patients with recurrent high-grade gliomas.
authors.affiliation: Ottawa Regional Cancer Centre, Ontario, Canada.
authors.forename: S Z
authors.initials: SZ
authors.lastname: Gertler
authors.forename: D
authors.initials: D
authors.lastname: MacDonald
authors.forename: M
authors.initials: M
authors.lastname: Goodyear
authors.forename: P
authors.initials: P
authors.lastname: Forsyth
authors.forename: D J
authors.initials: DJ
authors.lastname: Stewart
authors.forename: K
authors.initials: K
authors.lastname: Belanger
authors.forename: J
authors.initials: J
authors.lastname: Perry
authors.forename: D
authors.initials: D
authors.lastname: Fulton
authors.forename: W
authors.initials: W
authors.lastname: Steward
authors.forename: N
authors.initials: N
authors.lastname: Wainman
authors.forename: L
authors.initials: L
authors.lastname: Seymour
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D013256:Steroids / Q000627:therapeutic use; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D013256:Steroids; D003841:Deoxycytidine; D000093542:Gemcitabine